CT-2A Mouse Glioma Cell Line

Code: SCC194 D2-231

Application

Research CategoryCancerOncology

This product is intended for sale and sold solely to academic institutions for internal academic research use per the terms ...


read more

Your Price
€1,425.00 EACH
€1,752.75 inc. VAT

Application

Research CategoryCancerOncology

This product is intended for sale and sold solely to academic institutions for internal academic research use per the terms of the “Academic Use Agreement” as detailed in the product documentation. For information regarding any other use, please contact licensing@emdmillipore.com.

Cell Line Description

Cancer Cells

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

Glioblastomas are among the most aggressive forms of cancer, associated with low treatment efficacy and poor survival. Recurring glioblastomas are often resistant to first-line chemotherapies (1). There is much interest in studying drug-resistant forms of glioblastomas in the effort to develop effective therapies.

References:
1. Weller M, Cloughesy T, Perry JR, and Wick W (2013). Neuro Oncol 15(1): 4-27.
2. Seyfried TN, el-Abbadi M, and Roy ML (1992). Mol Chem Neuropathol 17(2):147-167.
3. Seyfried TN, Mukherjee P (2010). J Oncol 2010:961243 doi.10.1155/2010/961243.
4. Cotterchio M, Seyfried TN (1994). J Lipid Res 35(1): 10-14.
5. Binello E, Qadeer ZA, Kothari HP, Emdad L, Germano IM (2012). J Cancer 3: 166-174.
6. Martinez-Murillo R, Martinez A (2007). Histol Histopathol 22(12): 1309-1326.
7. Zimmerman HM and Arnold H. (1941). Cancer Res 1(12): 919-938.

The CT-2A cell line is derived from a sub-cutaneous, non-metastatic murine glioma (astrocytoma). The originating tumor was classified as poorly differentiated with high vascularity and malignancy (2). CT-2A cells are marked by high levels of complex gangliosides and low distribution of the anti-angiogenic ganglioside GM3, as well as deficiency in the tumor suppressor PTEN/TSC2, a characteristic present in up to 70% of human high-grade glioma cell lines (3,4). CT-2A tumors are wild-type for p53 and recapitulate several features of human high-grade glioma, including high mitotic index and cell density, nuclear polymorphism, hemorrhage, pseudopalisading necrosis, and microvascular proliferation (5,6).

Source:
CT-2A was generated from a malignant astrocytoma formed via implantation of the carcinogen 20-methylcholanthrene in the cerebrum of a C57BL/6J mouse (7). The tumor was maintained through serial intracranial transplants prior to cell line isolation.

Quality

Each vial contains ≥ 1X106 viable cells.
Cells are tested negative for infectious diseases by a Mouse Essential CLEAR panel by Charles River Animal Diagnostic Services.
Cells are verified to be of mouse origin and negative for inter-species contamination from rat, chinese hamster, Golden Syrian hamster, human and non-human primate (NHP) as assessed by a Contamination CLEAR panel by Charles River Animal Diagnostic Services.
Cells are negative for mycoplasma contamination

Storage and Stability

Store in liquid nitrogen. The cells can be cultured for at least 10 passages after initial thawing without significantly affecting the cell marker expression and functionality.

biological sourcemouse
shipped inambient
technique(s)cell culture | mammalian: suitable
This product has met the following criteria to qualify for the following awards:



PROCEED TO CHECKOUT

HAVE AN ACCOUNT? LOGIN


GUEST CHECKOUT

Proceed as a guest. You will have the option to register to access exclusive pricing and stock availability features after checkout.